美股新聞 標題聯播 · 近 24 小時 337 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · CRDF近 30 天 3 則 · 第 1 / 1 頁
- 3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets
- Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement
- Cardiff Oncology to Participate in September 2026 Conferences
- CRDF: Second Quarter Earnings
- Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update
- Cardiff Oncology Announces $10 Million Registered Direct Offering to Strengthen Working Capital
- Cardiff Oncology Announces $10 Million Registered Direct Offering
- Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential?
- CRDF: Phase II Update; Survival Advantage Extended
- Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting
- Kazia Therapeutics Appoints James Levine as Chief Financial Officer
- Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference
- CRDF: First Quarter 2026 Results
- Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
- Cardiff Oncology And 2 Other Promising Penny Stocks For Your Watchlist
- Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update
- Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Cardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity
- Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。